Phase 2 RCT in Kenyan children aged 5–59 months: two doses of monoclonal antibody L9LS vs placebo reduced P falciparum infection over 12 months (66% vs 83%; protective efficacy 42.7%), with no trial-related serious adverse events.
RCTn = 420
Steinhardt et al. Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial